{
    "clinical_study": {
        "@rank": "18276", 
        "arm_group": [
            {
                "arm_group_label": "Irbesartan alone", 
                "arm_group_type": "Other", 
                "description": "Irbesartan 300 mg alone"
            }, 
            {
                "arm_group_label": "Hydrochlorothiazide 25 mg alone", 
                "arm_group_type": "Other", 
                "description": "Hydrochlorothiazide 25 mg alone"
            }, 
            {
                "arm_group_label": "Irbesartan 300 mg + Hydrochlorothiazide 25 mg", 
                "arm_group_type": "Other", 
                "description": "Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination"
            }
        ], 
        "brief_summary": {
            "textblock": "This study was conducted to investigate any potential reaction between irbesartan and\n      hydrochlorothiazide."
        }, 
        "brief_title": "Drug Interaction Between Irbesartan and Hydrochlorothiazide", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        At least 18 years old and not more than 45 healthy normotensive male volunteers Who had\n        passed all the screening parameters\n\n        Exclusion Criteria:\n\n        A clinically significant abnormal physical exam, medical history, or laboratory studies If\n        they showed a sitting SBP of >140 or <100 mmHg, DBP > 90 or <60mm Hg, or a pulse rate of >\n        95 or < 50 beats/min at screening The use of any prescription drug within the previous\n        month or use of any over-the-counter medication within the past 14 days A history of blood\n        dyscrasias A history of alcohol or drug abuse within the past year Donation of blood\n        during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of\n        completing the study Unable to tolerate vein puncture and multiple blood samplings Any\n        surgical/medical condition that might alter drug absorption, distribution, metabolism, or\n        excretion"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858610", 
            "org_study_id": "PPT4"
        }, 
        "intervention": [
            {
                "arm_group_label": "Irbesartan 300 mg + Hydrochlorothiazide 25 mg", 
                "intervention_name": "Irbeasartan/hydrochlorothiazide", 
                "intervention_type": "Drug", 
                "other_name": "Fixed dose combination"
            }, 
            {
                "arm_group_label": "Irbesartan alone", 
                "intervention_name": "Irbesartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Hydrochlorothiazide 25 mg alone", 
                "intervention_name": "Hydrochlorothiazide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydrochlorothiazide", 
                "Irbesartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fixed dose combination", 
            "Pharmacokinetics", 
            "Irbesartan", 
            "Hydrochlorothiazide", 
            "Pharmacodynamics", 
            "Normotensive Participants"
        ], 
        "lastchanged_date": "May 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Damanhour", 
                    "country": "Egypt"
                }, 
                "name": "Pharmaceutics Department, Faculty of Pharmacy, Damanhour University"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Blood pressure (systolic/diastolic)", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 5 weeks"
            }, 
            {
                "measure": "pharmacokinetic parameter such as the Cmax of irbesartan and hydrochlorothiazide", 
                "safety_issue": "Yes", 
                "time_frame": "After collection of all blood samples, an expected average of 4 weeks"
            }, 
            {
                "measure": "Heart rate", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 5 weeks"
            }, 
            {
                "measure": "pharmacokinetic parameter such as the AUC of irbesartan and hydrochlorothiazide", 
                "safety_issue": "Yes", 
                "time_frame": "After collection of all blood samples, an expected average of 4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858610"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Damanhour University", 
            "investigator_full_name": "Sally Helmy, PhD, CPHQ", 
            "investigator_title": "Lecturer of Pharmaceutics, Faculty of Pharmacy", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Damanhour University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Damanhour University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}